ADVA
19.5.2020 09:02:13 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that dacoso is using its cloud-native security solution, ConnectGuard™ Cloud, to offer secure managed services. The virtualized encryption technology will give dacoso’s customers comprehensive data protection in cloud environments. With unprecedented scale and efficiency, dacoso will be able to roll out secure connectivity within minutes, safeguarding private, public, and edge/branch clouds at Layers 2, 3 and 4. Managed centrally in dacoso’s network by ADVA’s Ensemble Controller , the VPN services offer a major boost to the region’s businesses as they look to reduce costs and enhance flexibility by migrating more of their data and applications to the cloud. Now dacoso’s enterprise customers can harness the latest cloud tools while ensuring data integrity, regulatory compliance and true peace of mind for their end users.
“We’re excited to be offering our customers the comprehensive protection of ADVA’s ConnectGuard™ Cloud technology. For many of them, total cloud security is key to their business needs. By providing strong and flexible data protection in virtual environments, we’re enabling our customers to realize their full potential by accessing cloud applications with complete peace of mind,” said Karsten Geise, head of business and product development, dacoso. “We’re convinced by the robust security and performance benefits of ConnectGuard Cloud™. So much so that we’re already harnessing the solutions to protect our own branch and cloud locations. We understand its power to protect mission-critical data while also reducing costs and enhancing network utilization.”
Implemented entirely in software, ADVA’s ConnectGuard™ Cloud is a highly scalable, standards-compliant encryption solution that provides hybrid and multi-cloud environments with the ultimate defense against cyber threats. It enables dacoso to offer its customers high-performance, transport-layer-independent security with none of the performance issues of IPSec-based technologies. As a far more efficient and cost-effective alternative to hardware security appliances, ConnectGuard™ Cloud empowers dacoso’s customers to extend encryption to remote workers and branch offices by leveraging low-cost uCPE platforms. What’s more, with zero-touch provisioning, dacoso can roll out fully secured cloud connectivity almost instantly without any manual configuration.
“Our partnership with dacoso is great news for a huge number of enterprises across this region who are currently undergoing their digital transformation. With more and more of dacoso’s customers moving their workloads to cloud environments, our ConnectGuard™ Cloud technology provides the ideal way to ensure privacy and data integrity while keeping cost and complexity low,” commented Hartmut Müller-Leitloff, SVP, sales, EMEA, ADVA. “As a virtualized encryption solution with zero-touch provisioning and automated key management, our ConnectGuard™ Cloud is the most readily scalable option available. It improves operational simplicity and latency performance compared to appliance-based encryption methods. What’s more, it keeps latency at its lowest levels – a key requirement for many emerging cloud applications.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com
.
About dacoso
dacoso offers solutions for Connectivity, Virtual Networking and Cyber Security. The IT service provider thereby addresses companies that need their data to be highly available and secure yet without sacrificing agility. dacoso’s services comprise, among other, optical data links encrypted to satisfy BSI requirements (Federal Office for Information Security), a certified Security Operations Center, Managed Security Services and virtualization solutions to increase the dynamic performance of networks. dacoso GmbH is an owner-managed company headquartered in Langen near Frankfurt a.M. with a further 11 locations in Germany, Austria and Switzerland. www.dacoso.com
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200519005058/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
